Bipolar Disorder
Bipolar Disorder, previously known as manic depression, is a mental illness characterized by intense mood swings between emotional highs (mania or hypomania) and lows (depression), significantly impacting behavior, energy, and activity levels. During manic phases, individuals exhibit elevated moods, impulsivity, and reduced need for sleep, while depressive phases are marked by feelings of sadness, hopelessness, and high suicide risk, often associated with other mental health issues such as anxiety and substance use disorders.
Health Outcomes
- Alleviated Depression
- Altered Brain Activity to Negative Emotional Stimuli
- Altered Catecholamine Level
- Altered Monoamine Signaling
- Changed Functional Connectivity
- Elevated Serum Tryptophan Levels
- Enhanced BDNF-TrkB Signaling
- Enhanced Brain-Derived Neurotrophic Factor Levels
- Enhanced Neuropharmacological Function
- Enhanced Orbitofrontal Cortex Activation
- Enhanced Reward Responsiveness
- Enhanced Sensory Perception
- Improved Behavioral Abnormalities
- Improved Behavioral Elements
- Improved Brain-Derived Neurotrophic Factor Level
- Improved Coping Strategies
- Improved Depressive Symptoms
- Improved Depressive-Like Behaviours
- Improved Emotional Behavior
- Improved Emotional Dysregulation
- Improved Emotional Functioning
- Improved Emotional Well-Being Quality of Life
- Improved Emotional Well-being
- Improved Emotional and Behavioral Changes
- Improved Flexibility or Set Shift
- Improved General Behavioral Scores
- Improved Global Assessment of Efficacy
- Improved Global Clinical Impression
- Improved Inhibitory Executive Process
- Improved Medication Adherence
- Improved Mental Health
- Improved Mood Disturbance
- Improved Neuropsychiatric Outcomes
- Improved Neurotransmitter Metabolism
- Improved Perceived Mental Well-being
- Improved Positive Mood States
- Improved Problem-Solving Skills
- Improved Psychological Well-being
- Improved Psychosocial Domain Score
- Improved Psychosocial Health-Related Quality of Life
- Improved Role Emotional
- Improved Set Shifting Ability
- Improved Set-Shifting Reaction Time
- Improved Significant Response Rate
- Improved Social Functioning Quality of Life
- Improved Synaptic Plasticity
- Improved Temperament
- Improved Therapeutic Consistency
- Improved Total Mood
- Improved Treatment Compliance
- Improved Willingness to Continue Treatment
- Increased Anger/Hostility
- Increased Appetite
- Increased Arousal
- Increased BDNF Levels in the Prefrontal Cortex
- Increased Brain Choline Level
- Increased Brain GABA Levels
- Increased Brain-derived Neurotrophic Factor Level
- Increased Cortical Thickness
- Increased Distractibility
- Increased Dopamine Transporter Binding
- Increased Gray Matter Volume
- Increased Irritability
- Increased Locomotor Activity During Active Phase
- Increased Myo-Inositol Level
- Increased P3b Amplitude
- Increased Plasma Kynurenic Acid Levels
- Increased Plasma Serotonin Levels
- Increased Prefrontal Cortex Deoxygenated Hemoglobin Level
- Increased Production of Beneficial Neurotransmitter GABA
- Increased Serotonin 2A Receptor Levels
- Increased Serotonin Production
- Increased Serum BDNF Levels
- Maintained Normal Behavior
- Modulated HPA Axis
- Modulated Signal Transduction Pathways
- Neutral Blood Profile Impact
- No Adverse Effects on Food Intake
- No CYP1A2 or CYP3A4 Interaction
- No Change in Plasma GABA Levels
- No Significant Difference Compared to Placebo
- Normalized Neurotransmitter Levels
- Reduced ADAM Symptomatology Score
- Reduced Adherence Attrition
- Reduced Aggressive Feeling
- Reduced Agitation
- Reduced Anger
- Reduced Anhedonia
- Reduced Anthranilic Acid Level
- Reduced Behavioral Problem
- Reduced Behavioral Symptoms
- Reduced Brain Inflammation
- Reduced Depression Scores at Follow-Up
- Reduced Depressive Affect
- Reduced Depressive Behavior
- Reduced Depressive Thoughts
- Reduced Despair-Like Behavior
- Reduced Distress Symptoms
- Reduced Disturbed Sleep Night
- Reduced Episode Frequency
- Reduced Extrapyramidal Symptoms
- Reduced General Psychopathology
- Reduced General Psychopathology Score
- Reduced Gut Bacteria Associated with Mental Illness
- Reduced Hamilton Depression Rating Scale Score
- Reduced Impulsivity
- Reduced Indoleamine 2,3-Dioxygenase Activity
- Reduced Irritability
- Reduced Kynurenine Level
- Reduced Mania Symptoms
- Reduced Manic Symptoms
- Reduced Mood Lability
- Reduced N-acetylaspartate Level
- Reduced Negative Mood States
- Reduced Occurrence of Major Depressive Disorder
- Reduced P3b Amplitude
- Reduced Prefrontal Cortex Activation
- Reduced Prefrontal Cortex Oxygenated Hemoglobin
- Reduced Psychiatric Symptom
- Reduced Psychiatric Symptom Severity
- Reduced Psychological Distress
- Reduced Psychological Score
- Reduced Psychopathology Symptoms
- Reduced Psychosocial Symptom
- Reduced Relapse
- Reduced Relapse Rate
- Reduced Seasonal Affective Disorder Symptom
- Reduced Serum BDNF Levels
- Reduced Serum Glutamate Levels
- Reduced Set-Shifting Reversal Error
- Reduced Stroop Reaction Time
- Reduced Suicide Attempt
- Reduced Suicide Ideation
- Reduced Suicide-Related Emergency or Hospital Visit
- Reduced Suicide-Related Endpoints
- Reduced Sympathetic Nerve Activity
- Reduced Total Side Effects Incidence
- Reduced Treatment Discontinuation
- Regulation of Neuroactive Ligand Receptor Interaction Pathway
- Stabilized Dopamine Pathway Function
- Worsened Depression Score
- Worsened Inhibitory Control